Cost-Effectiveness of Genotype-Guided Warfarin Dosing for Patients With Atrial Fibrillation

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Circulation. Cardiovascular Quality and Outcomes

• Publication date

  2009-07-21

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.1161/CIRCOUTCOMES.108.808592PMID 20031873
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cost-effectiveness in health and medicine

  2016cited by this paper
• CYP2C9 Genotype‐guided Warfarin Prescribing Enhances the Efficacy and Safety of Anticoagulation: A Prospective Randomized Controlled Study

  2008cited by this paper
• Healthcare impact of personalized medicine using genetic testing: an exploratory analysis for warfarin.

  2008cited by this paper
• Genetic determinants of response to warfarin during initial anticoagulation.

  2008cited by this paper
• Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation

  2008cited by this paper
• Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study.

  2007cited by this paper
• Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation

  2007cited by this paper
• The cost‐effectiveness of warfarin pharmacogenomics

  2007cited by this paper
• Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation

  2007cited by this paper
• Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation

  2007cited by this paper
• Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis.

  2006cited by this paper
• CYP2C9 genotyping in acenocoumarol treatment: Is it a cost‐effective addition to international normalized ratio monitoring?

  2006cited by this paper
• Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation.

  2005cited by this paper
• Time Trends of Ischemic Stroke Incidence and Mortality in Patients Diagnosed With First Atrial Fibrillation in 1980 to 2000: Report of a Community-Based Study

  2005cited by this paper
• Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.

  2005cited by this paper
• The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.

  2005cited by this paper
• Trends in incidence and mortality in the hospital diagnosis of atrial fibrillation or flutter in Denmark, 1980-1999.

  2005cited by this paper
• A National Catalog of Preference-Based Scores for Chronic Conditions in the United States

  2005cited by this paper
• A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data.

  2005cited by this paper
• Copyright

  2005cited by this paper
• Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty.

  2005cited by this paper
• Brief reflections on treatment satisfaction.

  2005cited by this paper
• The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage.

  2004cited by this paper
• The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy – a decision analysis

  2004cited by this paper
• Risk Adjustment of Medicare Capitation Payments Using the CMS-HCC Model

  2004cited by this paper
• Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.

  2003cited by this paper
• Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?

  2003cited by this paper
• Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin

  2003cited by this paper
• Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial.

  2002cited by this paper
• Health Economic Evaluations: The Special Case of End-Stage Renal Disease Treatment

  2002cited by this paper
• Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.

  2002cited by this paper
• Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.

  2001cited by this paper
• Are the results of randomized controlled trials on anticoagulation in patients with atrial fibrillation generalizable to clinical practice?

  2001cited by this paper
• Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.

  2001cited by this paper
• Genetic Modulation of Oral Anticoagulation with Warfarin

  2000cited by this paper
• Management and dosing of warfarin therapy.

  2000cited by this paper
• Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation

  1999cited by this paper
• Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.

  1999cited by this paper
• The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life.

  1996cited by this paper
• Risk Factors for Intracranial Hemorrhage in Outpatients Taking Warfarin

  1994cited by this paper
• Markov Models in Medical Decision Making

  1993cited by this paper
• How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations.

  1992cited by this paper
• Department of Labor

  1941cited by this paper

• Subgroup analysis of genotype guided vs traditional warfarin dosing in Asian patients from an open label randomized trial

  2026cites this paper
• Pharmacogenetic guided versus standard warfarin dosing for routine clinical care with its pharmacoeconomic impact: a randomized controlled clinical trial

  2024cites this paper
• Cost Effectiveness of Pharmacogenetic Testing for Drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines: A Systematic Review

  2022cites this paper
• Pharmacogenetic testing for adverse drug reaction prevention: systematic review of economic evaluations and the appraisal of quality matters for clinical practice and implementation

  2021cites this paper
• Genetic-Guided Pharmacotherapy for Atrial Fibrillation: A Systematic and Critical Review of Economic Evaluations.

  2021cites this paper
• Pharmacogenomics

  2020cites this paper
• Genotype‐guided warfarin therapy: Still of only questionable value two decades on

  2020cites this paper
• Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention.

  2020cites this paper
• Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data

  2020cites this paper
• Outpatient Oral Anticoagulant Therapy

  2019cites this paper
• Accounting for Capacity Constraints in Economic Evaluations of Precision Medicine: A Systematic Review

  2019cites this paper
• Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases

  2019cites this paper
• Implementation of Pharmacogenomics in Everyday Clinical Settings.

  2018cites this paper
• Benefit of Preemptive Pharmacogenetic Information on Clinical Outcome

  2018cites this paper
• Improving Outcomes and Reducing Healthcare Costs for Diabetes and Its Comorbidities With Pharmacogenetics Guided Medication Therapy

  2018cites this paper
• Genotype-guided warfarin therapy: current status.

  2018cites this paper
• Optimizing quality care for the oral vitamin K antagonists (VKAs).

  2018cites this paper
• Warfarin Pharmacogenomics in Diverse Populations

  2017cites this paper
• Cost-Utility Study of Warfarin Genotyping in the VACHS Affiliated Anticoagulation Clinic of Puerto Rico.

  2017cites this paper
• Cost-effectiveness analysis of patient self-testing therapy of oral anticoagulation

  2017cites this paper
• Cost Effectiveness of Genotype-Guided Warfarin Dosing in Patients with Mechanical Heart Valve Replacement Under the Fee-for-Service System

  2017cites this paper
• The Value of Evidence in the Decision-Making Process for Reimbursement of Pharmacogenetic Dosing of Warfarin

  2017cites this paper
• Risk of development of hemorrhagic complications due to warfarin therapy

  2017cites this paper
• Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?

  2016cites this paper
• Optimizing treatment with psychotropic agents through precision drug therapy

  2016cites this paper
• Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature

  2016influential citation
• GWAS for Drug Discovery

  2016cites this paper
• Designing Personalized Treatment: An Application to Anticoagulation Therapy

  2016cites this paper
• A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions

  2016cites this paper
• Pharmacogenetics and oral antithrombotic drugs.

  2016cites this paper
• Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics

  2015cites this paper
• Economic evaluation of pharmacogenomic-guided warfarin treatment for elderly Croatian atrial fibrillation patients with ischemic stroke.

  2015cites this paper
• Meta-analysis of Randomized Controlled Trials of Genotype-Guided vs Standard Dosing of Warfarin.

  2015cites this paper
• Financial Analysis of CYP 2 C 19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention

  2015cites this paper
• Assessing the Costs and Cost-Effectiveness of Genomic Sequencing

  2015cites this paper
• Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention.

  2015cites this paper
• Genotype-guided coumarin dosing: where are we now and where do we need to go next?

  2015influential citation
• A Health Economic Evaluation of Stroke Prevention in Atrial Fibrillation: Guideline Adherence Versus the Observed Treatment Strategy Prior to 2012 in Denmark

  2015cites this paper
• Pharmacogenetics of coumarin anticoagulant therapy

  2015cites this paper
• Economic evaluation of a pharmacogenetic dosing algorithm for coumarin anticoagulants in The Netherlands.

  2015cites this paper
• Cost-effectiveness analysis of pharmacogenetic-guided warfarin dosing in Thailand.

  2014influential citation
• Personalized Medicine’s Bottleneck: Diagnostic Test Evidence and Reimbursement

  2014cites this paper
• 한국 비판막성 심방세동 환자의 뇌졸중 위험 감소에 대한 리바록사반의 경제성평가

  2014cites this paper
• Cost‐Effectiveness of Pharmacogenetics‐Guided Warfarin Therapy vs. Alternative Anticoagulation in Atrial Fibrillation

  2014cites this paper
• Genotype-guided use of oral antithrombotic therapy: a pharmacoeconomic perspective.

  2014cites this paper
• Warfarin dosing by genotype did not improve time in therapeutic range

  2014cites this paper
• Economic Evaluation of Using a Genetic Test to Direct Breast Cancer Chemoprevention in White Women with a Previous Breast Biopsy

  2014cites this paper
• High resolution melting method to detect single nucleotide polymorphism of VKORC 1 and CYP 2 C 9

  2014cites this paper
• Cost-effectiveness analysis of extended duration anticoagulation with rivaroxaban to prevent recurrent venous thromboembolism.

  2014cites this paper
• High resolution melting method to detect single nucleotide polymorphism of VKORC1 and CYP2C9.

  2014cites this paper
• Cost-effectiveness of pharmacist-participated warfarin therapy management in Thailand.

  2013cites this paper
• Cost-Effectiveness of Oral Anticoagulants for Treatment of Atrial Fibrillation

  2013cites this paper
• Economic analyses of genetic tests in personalized medicine: clinical utility first, then cost utility

  2013cites this paper
• Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: a cost/utility analysis using an analytic decision model

  2013cites this paper
• Review of Economics and Cost-Effectiveness Analyses of Anticoagulant Therapy for Stroke Prevention in Atrial Fibrillation in the US

  2013cites this paper
• Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation.

  2013cites this paper
• Oral Anticoagulation in Elderly Adults with Atrial Fibrillation: Integrating New Options with Old Concepts

  2013cites this paper
• Pharmacogenetic testing: current evidence of clinical utility

  2013cites this paper
• Willingness-to-pay and preferences for warfarin pharmacogenetic testing in Chinese warfarin patients and the Chinese general public.

  2013cites this paper
• Pharmacogenetics of Oral Anticoagulants and Antiplatelets

  2013cites this paper
• Personalised treatment with oral anticoagulant drugs : clinical and economic issues

  2013cites this paper
• 39 – Outpatient Anticoagulant Therapy

  2013cites this paper
• Genomic, Personalized Medicine and Public Health

  2013cites this paper
• Chapter 4 – Pharmacogenetics

  2013cites this paper
• Evaluación económica del tratamiento de la trombocitopenia inmune primaria crónica refractaria con agonistas del receptor de la trombopoyetina

  2013cites this paper
• Personalized Medicine

  2013cites this paper
• Effect of Genetic Variants, Especially CYP2C9 and VKORC1, on the Pharmacology of Warfarin

  2012cites this paper
• Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  2012cites this paper
• Pharmacologically-based mechanistic modelling in health economic evaluation

  2012cites this paper
• Schwerwiegende Arzneimittelnebenwirkungen von Phenprocoumon: stationäre Kosten der gastrointestinalen Blutungen und Einsparungspotentiale

  2012cites this paper
• Cost-Effectiveness of Apixaban Compared With Aspirin for Stroke Prevention in Atrial Fibrillation Among Patients Unsuitable for Warfarin

  2012cites this paper
• Perceval sutureless approach in a patient with porcelain aorta unsuitable for transcatheter aortic valve implantation.

  2012cites this paper
• Cost Effectiveness of Pharmacogenomics

  2012influential citation
• Personalized medicine: is it a pharmacogenetic mirage?

  2012cites this paper
• Bewertung der Einsparpotenziale in der Arzneimitteltherapie durch Dosisanpassung an die Polymorphismen im Cytochrom P450

  2012cites this paper
• Challenges and opportunities in implementing pharmacogenomics testing in the clinics.

  2012cites this paper
• Evaluation of economic savings in drug therapy by dose adjustment to polymorphisms in cytochrome P450

  2012cites this paper
• Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable.

  2012cites this paper
• Pharmacogenetics and anaesthesia: the value of genetic profiling

  2012cites this paper
• Personalized Medicine in the Genomics Era: highlights from an international symposium on childhood heart disease.

  2012cites this paper
• Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs.

  2012cites this paper
• Optimizing Drug Outcomes Through Pharmacogenetics: A Case for Preemptive Genotyping

  2012cites this paper
• The interaction between fluvastatin and warfarin.

  2012cites this paper
• Pharmacoeconomic evaluation of warfarin pharmacogenomics

  2011cites this paper
• Jerry Avorn Effectiveness The Relative Cost-Effectiveness of Anticoagulants : Obvious , Except for the Cost and the

  2011cites this paper
• Role of Pharmacogenomics in the Management of Traditional and Novel Oral Anticoagulants

  2011cites this paper
• The relative cost-effectiveness of anticoagulants: obvious, except for the cost and the effectiveness.

  2011cites this paper
• Genome-wide association studies of antidepressant outcome: a brief review.

  2011cites this paper
• Pharmacogenomic testing: Relevance in medical practice

  2011cites this paper
• Clinical applications of pharmacogenomics guided warfarin dosing

  2011cites this paper
• Predicting warfarin dose

  2010cites this paper
• A formal risk-benefit framework for genomic tests: Facilitating the appropriate translation of genomics into clinical practice

  2010cites this paper
• University of Groningen Economic Evaluations of Pharmacogenetic and Genomic Screening Programs Vegter,

  2010influential citation
• Real warfarin resistance or medication noncompliance

  2010cites this paper
• Clinical applications of pharmacogenomics guided warfarin dosing

  2010cites this paper
• Economic evaluations of pharmacogenetic and genomic screening programs: update of the literature

  2010influential citation
• Clinical and economic consequences of pharmacogenetic-guided dosing of warfarin

  2010cites this paper
• Clinical and economic consequences of pharmacogenetic-guided

  2010cites this paper
• Focusing on outcomes in Circulation: Cardiovascular Quality and Outcomes.

  2010cites this paper
• Systematic review of pharmacoeconomic studies of pharmacogenomic tests.

  2010cites this paper